Binding of a new thyroid-stimulating human monoclonal autoantibody (MAb) K1-18 to the TSH receptor (TSHR) leucinerich domain (LRD) was predicted using charge-charge interaction mapping based on unique complementarities between the TSHR in interactions with the thyroid-stimulating human MAb M22 or the thyroid-blocking human MAb K1-70. The interactions of K1-18 with the TSHR LRD were compared with the interactions in the crystal structures of the M22-TSHR LRD and K1-70-TSHR LRD complexes. Furthermore, the predicted position of K1-18 on the TSHR was validated by the effects of TSHR mutations on the stimulating activity of K1-18. A similar approach was adopted for predicting binding of a mouse thyroid-blocking MAb RSR-B2 to the TSHR. K1-18 is predicted to bind to the TSHR LRD in a similar way as TSH and M22. The binding analysis suggests that K1-18 light chain (LC) mimics binding of the TSH-a chain and the heavy chain (HC) mimics binding of the TSH-b chain. By contrast, M22 HC mimics the interactions of TSH-a while M22 LC mimics TSH-b in interactions with the TSHR. The observed interactions in the M22-TSHR LRD and K1-70-TSHR LRD complexes (crystal structures) with TSH-TSHR LRD (comparative model) and K1-18-TSHR LRD (predictive binding) suggest that K1-18 and M22 interactions with the receptor may reflect interaction of thyroid-stimulating autoantibodies in general. Furthermore, K1-70 and RSR-B2 interactions with the TSHR LRD may reflect binding of TSHR-blocking autoantibodies in general.
Introduction
K1-18 is a TSH receptor (TSHR) human monoclonal autoantibody (MAb; IgG1/kappa) with the ability to stimulate cAMP production in TSHR-transfected CHO cells and to inhibit TSH binding to the receptor at nanogram per millilitre concentrations , Evans et al. 2010 . K1-18 has high binding affinity for the TSHR of w6 . 7!10 9 l/mol, and the characteristics of K1-18 fulfil the criteria set out for human TSHR MAbs (McLachlan & Rapoport 1996) . To date, the crystal structures of a thyroidstimulating human MAb M22 (1 . 65 Å resolution; Sanders et al. 2004 ) and a thyroid-blocking human MAb K1-70 (2 . 22 Å resolution; Sanders et al. 2011) have been described. In addition, a mouse TSHR MAb (RSR-B2) with potent TSH-binding inhibiting and TSHR antagonist activities has also been crystallised (3 . 30 Å resolution; Sanders et al. 2005) . TSHR amino acids involved in the interactions of RSR-B2 were identified in a series of experiments with mutated TSHR (Sanders et al. 2006 . The structures of the TSHR leucine-rich domain (LRD) in complex with M22 (2 . 55 Å ; Sanders et al. 2007a ) and with K1-70 (1 . 9 Å ; Sanders et al. 2011) provided molecular details of the interactions of M22 and K1-70 with the receptor. To study the interactions of TSH with the TSHR, a comparative model of a TSH-TSHR LRD complex has been produced using the crystal structures of M22-TSHR LRD (Sanders et al. 2007a) and FSH-FSH receptor (FSHR; Fan & Hendrickson 2005) complexes to model the binding arrangements between TSH and the TSHR (Nú ñez Miguel et al. 2008) .
We now describe the crystal structure of K1-18 Fab solved at 1 . 65 Å resolution. The K1-18 structure was then compared with the structures of the thyroidstimulating human MAb M22 and the thyroid-blocking human MAb K1-70 (Sanders et al. 2011) . Furthermore, the mouse MAb RSR-B2 that has the characteristics of human thyroid-blocking autoantibodies (Sanders et al. 2006 ) was included in the study. In particular, features of the electrostatic potential surfaces of the four MAbs were studied. Binding of K1-18 to the TSHR LRD was then predicted using charge-charge interaction mapping based on unique complementarities between the TSHR LRD in interaction with the thyroid-stimulating human MAb M22 (Sanders et al. 2007a) or the thyroid-blocking human MAb K1-70 (Sanders et al. 2011) . The predicted binding of K1-18 to the TSHR LRD was validated by the effects of TSHR mutations on the stimulating activity of K1-18. A similar approach has also been used to predict the relative position of the thyroid-blocking mouse MAb RSR-B2 on the TSHR.
Materials and methods
Preparation of K1-18 Fab K1-18 IgG was prepared from heterohybridoma culture supernatants using protein A affinity chromatography on MabSelect (GE Healthcare, Little Chalfont, UK) according to the manufacturer's instructions. The purified IgG was treated with mercuripapain (SigmaAldrich) at an enzyme/protein (w/w) ratio of 1:300, EDTA at a final concentration of 2 mmol/l and L-cysteine at a final concentration of 1 mmol/l for 2 h at 37 8C. The reaction was terminated by addition of 50 mmol/l iodoacetamide in 2 mmol/l Tris-HCl (pH 8 . 3) for 30 min at room temperature. The digest was passed through a MabSelect column to remove any intact IgG or Fc from the Fab preparation. K1-18 Fab was dialysed into PBS (137 mmol/l NaCl, 8 . 1 mmol/l NaHPO 4 , 2 . 7 mmol/l KCl, 1 . 47 mmol/l KH 2 PO 4 , pH 7 . 4) containing 0 . 2 g/l sodium azide and concentrated to 8 . 0 mg/ml using 20 ml 9 kDa MWCO iCON concentrators (Thermo Scientific, Cramlington, UK). The K1-18 Fab was further purified on a preparative Superdex 75 column using an AKTA platform (GE Healthcare), the peak fractions were pooled and concentrated to 9 . 3 mg/ml using iCON concentrators.
The final K1-18 Fab was analysed by SDS-PAGE, sizeexclusion HPLC and for inhibition of TSH-biotin binding to the TSHR . For crystallisation trials the K1-18 Fab was buffer exchanged into 500 mmol/l NaCl, 10 mmol/l Tris-HCl, pH 7 . 4 and concentrated to 20 mg/ml (Evans et al. 2010 ).
X-ray diffraction and structure determination of K1-18 Fab K1-18 crystals were grown using the hanging drop vapour diffusion method in wells containing 15% PEG 3350, 200 mmol/l Li 2 SO 4 and 100 mmol/l Tris-HCl, pH 8 . 5. A single crystal of dimensions 0 . 4!0 . 2!0 . 1 mm was transferred into an 80% well solution and 20% glycerol mix, and flash frozen in liquid nitrogen. The data set was collected using a Rigaku-007HF generator and an R-Axis IV image plate detector and indexed, integrated and scaled using MOSFLM and SCALA (Biofocus, Saffron Walden, UK). The structure of K1-18 Fab was determined by the molecular replacement method using the PDB coordinates of 1U6A for the light chain (LC) domains and 2VXV for the heavy chain (HC) domains. Molecular replacement was performed using the programme PHASER (Collaborative Computational Project number 4 (CCP4) 1994) and the resulting model refined with tight geometric weights using REFMAC5 (CCP4). Electron density maps calculated after initial refinement were examined using COOT (Emsley et al. 2010) and automatically corrected and rebuilt using BUCCANEER (CCP4). Structural geometry of K1-18 Fab was checked using PROCHECK (Laskowski et al. 1993; CCP4) and RAMPAGE (CCP4) and the residues were numbered in accordance with the Kabat system (Kabat et al. 1991) .
Stimulation of cAMP production by K1-18 IgG in CHO cells expressing wild type or mutated TSHRs
Point mutations in the TSHR amino acid sequence were introduced using the Flp-In-CHO system (Invitrogen) as described previously (Sanders et al. 2006) . The presence of mutation was verified by amino acid sequence analysis (Geneservice Ltd., Cambridge, UK). The ability of K1-18 IgG to stimulate the production of cAMP in CHO cells expressing either WT or mutated TSHRs was tested as described before (Sanders et al. 2006) . In these experiments, dilutions of porcine TSH (75 units/mg from RSR; 0 . 01-3 ng/ml) and K1-18 IgG (0 . 3-100 ng/ml) in cAMP assay buffer (NaCl-free Hank's Buffered Salts solution containing 1 g/l glucose, 20 mmol/l HEPES, 222 mmol/l sucrose, 15 g/l BSA and 0 . 5 mmol/l 3-isobutyl-1-methyl xanthine, pH 7 . 4) were used and cyclic AMP concentration in the lysates were determined using the Assay Designs Direct Cyclic AMP Correlate-EIA Kit (Enzo Life Sciences (UK) Ltd, Exeter, UK) following the manufacturer's instructions. Relative effects of TSHR mutations were expressed as a percentage of activity observed with WT (i.e. CCCCC, 100% of WT activity; CCCC, !100-80% of WT activity; CCC, !80-60% of WT activity; CC, !60-40% of WT activity; C, !40-20% of WT activity and 0, !20% of WT activity).
In all experiments with both WT and mutated TSHRs, cAMP response to different concentrations of TSH was studied alongside the test ligand. TSH response acted as a reference to assess the threedimensional integrity of the mutated TSHR. For example, if the TSHR mutation had no effect on TSH activity relative to the WT but affected the activity of the test ligand, this was classed as an effect. However, TSHR residues that when mutated affected the activity of TSH to the same extent as the activity of the test ligand that was not classed as interacting residues as the observed effect may be due to conformational changes in the receptor. The use of TSH as a reference in all experiments was employed in our previous studies and allowed us to compare old and new data sets (Sanders et al. 2006 (Sanders et al. , 2007a (Sanders et al. ,b, 2010 (Sanders et al. , 2011 .
Non-bonding interactions and protein-protein complex interface analysis
Van der Waals interactions between residues and interface surfaces of the complexes were studied using accessible surface areas (ASAs), calculated by the Discovery Studio 2.5.5 programme (DS 2.5.5, Accelrys, Inc., San Diego, CA, USA), which uses an enhanced grid-based numerical algorithm, similar to conventional methods. Interface residues were defined as the residues that possessed an ASA that decreased (DASA) by more than 1 Å 2 on complexation (Jones & Thornton 1996) . Electrostatic potential surfaces of the interacting surfaces of proteins were generated using PyMOL (DeLano 2002) .
The number and type of non-bonding interactions between residues/atoms of the interfaces of the proteins were obtained by the in-house programme CONTACTS (R Nú ñ ez Miguel 2008, unpublished observations). In our analyses, the maximum distance considered for hydrogen bonds was 3 . 5 Å , for van der Waals interactions 4 Å and for charged electrostatic interactions 7 Å . In the study of charge-charge interactions, a 'salt bridge' was considered when the atomic distance between the two charged atoms was %3 . 5 Å , an 'ion pair' was considered when the atomic distance was O3 . 5 and %4 . 5 Å , and those at the distance longer than 4 . 5 Å were considered to be 'solvent-separated ion pairs'.
To study the features of the antigen-binding sites of the three TSHR human autoantibodies, a superimposition of the coordinates of the variable domains of the respective Fab fragments was carried out using the programme Discovery Studio 2.5.5 (DS 2.5.5, Accelrys, Inc.).
The amino acid hydrophobicity profiles were calculated using an in-house programme based on the Kyte & Doolittle hydrophobicity scale (Kyte & Doolittle 1982) with a window size of seven residues, window edge relative weight of 10% and an exponential weight variation model (Gasteiger et al. 2005) . Protein surfaces were generated by PyMOL (DeLano 2002) and coloured according to the hydrophobicity profile using a yellow white green ramp. Negative profile values (hydrophilic residues) were coloured in yellow, near zero profile values were coloured in white, and positive profile values (hydrophobic residues) were coloured in green.
Results

Crystal structure of K1-18 Fab
The structure of K1-18 Fab was determined at 1 . 65 Å resolution with a R work factor of 18 . 3% and an R free factor of 22 . 0% ( A similar distribution of polar and charged residues was (Fig. 1) is a highly irregular surface dominated by acidic patches on one side, low potential basic patches on the other side and a central positive patch. The acidic patches are centred on HC residues: D54, D56 and E64 (CDR2), and D97, D100C and D101 (CDR3).
The low potential basic patches are centred on residues R24 (CDR1 LC), R54 (CDR2 LC) and R96 (CDR3 HC) and the central positive patch is formed by residues R96 (CDR3 LC) and R58 (CDR2 HC). The surface of K1-18 Fab also contains 11 aromatic residues, the majority of which are contributed from the HC (Table 2 ). In contrast to M22 or K1-70, there are no cavities on the surface of K1-18 (Fig. 1 ). Figure 1 also shows that the antigen-binding sites of the three human autoantibodies (K1-18, M22 and K1-70) are mostly hydrophilic with no hydrophobic patches on their surfaces. By contrast, the antigen-binding site of the mouse antibody (RSR-B2), which is also predominantly hydrophilic, shows some hydrophobic patches on its surface (Fig. 1) .
Comparison of structures of TSHR MAbs
Analysis of the amino acid sequences of K1-18, K1-70 and M22 indicated that K1-18 has fewer charged residues in the LC CDRs than K1-70 and M22, while the K1-18 HC CDRs contain more charged residues than K1-70 and M22 ( Table 2 ). The aromatic residues on the antigen-binding surface of K1-18 and M22 are contributed predominantly from the HCs (9/11 and 8/11 respectively), while K1-70 HC contributes 8/14 of the aromatic residues ( Fig. 1 and Table 2 ). Although the three antibodies have a similar number of aromatic amino acids in their CDRs, M22 has fewer aliphatic amino acids in the CDRs compared with K1-18 and K1-70 (Table 2) .
The K1-18 LC cysteine 91 (LC CDR3) in the structure is modified to cysteine-S-acetamide, while in the case of K1-70 and M22 there is a tryptophan at the equivalent position. However, K1-18 LC 91 cysteine-S-acetamide occupies a similar space in the K1-18 Fab structure as a tryptophan in the M22 and K1-70 structures. In the M22 and K1-70 crystal structures, the LC 91 tryptophan does not make interactions with the TSHR LRD and a similar scenario is likely for K1-18 LC91.
The elbow angle of K1-18 in the crystal structure was 169 . 18. In the case of the K1-70 structure there were two Fab molecules in the unit cell with different elbow angles: Fab AZ145 . 58 and Fab BZ163 . 18 (Stanfield et al. 2006 , Sanders et al. 2011 . The elbow angle of unbound M22 (1 . 65 Å resolution) was 227 . 18, whereas M22 bound to the TSHR LRD (2 . 55 Å resolution) had an elbow angle of 162 . 08 (Sanders et al. , 2007a ; Table 2 ). The elbow angle arrangements in the structure of unbound M22 resulted in M22 HC protruding farther away from the Fab structure than M22 LC . By contrast, in the case of K1-70 (unbound and bound to the TSHR) and K1-18 (unbound) , the relative positions of the HC and LC in the structure are more symmetrical than in the M22 structure. A superimposition of the variable domains of unbound K1-18, K1-70 and M22 gave root mean square deviation (RMSD) values of 2 . 01 Å (K1-18 and K1-70), 1 . 83 Å (K1-18 and M22) and 1 . 02 Å (K1-70 and M22) for all Ca atoms. The backbones of the combining sites of K1-70 and M22 show highly similar structures consistent with the canonical class of antibodies. The backbone of the combining site of K1-18 (IgG1/kappa) differs slightly from K1-70 (IgG1/lambda) and M22 (IgG1/lambda) due to differences in the type of the LC.
The electrostatic potential surface of K1-18 is characterised by a central positive patch flanked on one side by a negatively charged area and the other side by a low potential positively charged area. The negatively charged residues are contributed mostly from K1-18 HC, while the positively charged residues are from the LC (Fig. 1) . In the case of K1-70, one side of the antigen-binding site is characterised by a large negatively charged area that contains a small positive patch within, while the other side is predominantly positively charged. The negative charge is contributed mainly from HC residues and the positive charge from LC residues (Fig. 1) . The charge distribution on the surface of M22 is opposite to that on K1-70; an area contributed from the HC is predominantly positively charged, whereas the area formed mainly by LC residues is predominantly negatively charged with a small positive patch contained within (Fig. 1) . Overall, the electrostatic potential surfaces of the three antibodies, although different, have some characteristics in common, in particular all three combining sites contain a positive patch surrounded by a negative patch (Fig. 1) .
In addition, the crystal structure of the TSHRblocking mouse antibody RSR-B2 solved at 3 . 30 Å ) was compared with the human MAbs (K1-18, M22 and K1-70). The structure of RSR-B2 is that of a standard Fab fragment with a kappa LC.
It shows an elbow angle of 159 . 68, which is similar to the other three antibodies ( Table 2 ). The combining region of the RSR-B2 antigen-binding site ( Fig. 1 ) is highly irregular with a cavity in its centre similar to M22 and K1-70. The aromatic residues on the antigenbinding surface of RSR-B2 are contributed predominantly from the HC (8/11) similar to M22 and K1-18. There are only eight charged residues; two from the LC and six from the HC ( Table 2) . The electrostatic potential surface shows a low potential positive patch in the centre surrounded by negative patches. The acidic patches are centred on LC residue D50 (CDR2) and HC residues E50, D52 and D54 (CDR2), and D101 (CDR3). The low potential basic patch is centred on LC residues H34 (CDR1) and W91 (CDR3). Although the striking polarity in charge distribution on both sides of the antigen-binding surface is less evident, RSR-B2 also contains a low potential positive patch surrounded by a negative patch on its surface similar to M22, K1-18 and K1-70 ( Fig. 1 ; Sanders et al. 2011) . Effect of TSHR LRD mutations on K1-18 cAMP-stimulating activity
The effects of different amino acid mutations in the TSHR extracellular domain on the ability of K1-18 to stimulate cAMP production in CHO cells expressing the mutated TSHR are shown in Table 3 . Mutation of TSHR residues D43, K58, I60, E61, H105, F134, Y148, E178, Y195, K201, D203, Y225, Q235, S243, D247, K250, E251, T257, D276 and S281 to alanine showed no significant effect (compared with WT TSHR) on stimulation of cAMP production by the stimulating antibodies K1-18 or M22 (Table 3 and Fig. 2 ). By contrast, TSHR mutations E157A, D160K, K183A, K183D, Y185A, Y206A, D232A, R255D, W258A and R274A caused a loss or decrease of K1-18 ability to stimulate cAMP production (Table 3 and Fig. 2 ). The TSHR mutations R80A, R80D, Y82A, H105D, E107A, R109A, K129A, F130A, D151A, D151R, F153A, K209A, K209E and R255A had an effect on M22 cAMPstimulating activity (complete or partial reduction) but had no effect on K1-18 stimulation of cAMP (Table 3) . However, six TSHR mutations-K183A, K183D, Y185A, D232A, R255D and W258A-affected both K1-18 and M22 stimulation of cAMP production to a greater extent than TSH (Table 3) . By contrast, five TSHR mutations-R38A, E107R, R109D, K129D and D160A-all affected TSH stimulation to a similar or greater extent compared with K1-18 (Table 3 and Fig. 2) , and in this case it was difficult to determine whether these amino acids were important for K1-18 binding and stimulating activity or for the correct folding of the receptor itself.
Charge-charge interaction mapping of antibody binding to the TSHR LRD Analysis of the crystal structures of the TSHR LRD in complex with both the blocking MAb K1-70 and the stimulating MAb M22 showed that the charged patches on the surface of TSHR MAbs interact with complementary patches on the concave face of the TSHR LRD (Sanders et al. 2007a (Sanders et al. , 2011 . In particular, an area with a similar electrostatic potential present on both antibody-combining sites (positive patch surrounded by a circular negative patch) interacts with a complementary charged area on the TSHR LRD ( Fig. 3A and B). As seen in Fig. 3A and B, the same charged areas on the TSHR LRD surface tend to form interactions with both antibodies. In addition, analysis of the electrostatic potential surface of TSH (Núñez Miguel et al. 2008) showed similarities in the distribution of charged patches compared with M22 and K1-70. Furthermore, the charge-charge interactions observed in the model of the TSH-TSHR LRD complex showed similarities to the interactions in the M22-TSHR LRD and K1-70-TSHR 
Relative effects of TSHR mutations were expressed as a percentage of activity observed with WT (i.e. CCCCC, 100% of WT activity; CCCC, !100-80% of WT activity; CCC, !80-60% of WT activity; CC, !60-40% of WT activity; C, !40-20% of WT activity; 0, !20% of WT activity). NT, not tested. a The effect of TSHR mutations on the stimulation of cyclic AMP production by M22 is from Sanders et al. (2006 Sanders et al. ( , 2007a .
LRD complexes ( Fig. 3E ; Sanders et al. 2007a , Núñez Miguel et al. 2008 ).
In particular, several patches with a similar charge can be identified on the surface of the three ligands (M22, K1-70 and TSH) that interact with the same charged patches on the concave surface of the TSHR LRD (Fig. 4A ). In addition, some patches on K1-70 and TSH are complementary to the same patches on the surface of the TSHR LRD (Fig. 4C ) and some patches on M22 and TSH are complementary to the same patches on the TSHR LRD (Fig. 4B) .
The observations on charge-charge interactions described earlier were used to predict the relative position of K1-18 and RSR-B2 with respect to the concave surface of TSHR LRD (Fig. 3C and D) . The predicted positions were validated by the effect of TSHR amino acid mutations on cAMP activity of RSR-B2 (Sanders et al. 2006 and K1-18.
In the predicted K1-18-TSHR complex, K1-18 combines with a similar area on the TSHR LRD as M22 but is rotated by w1908 about an axis perpendicular to the concave surface of the TSHR LRD. In this arrangement the K1-18 LC interacts with an area on the TSHR similar to the area that interacts with M22 HC, and the K1-18 HC binds to a region on the TSHR that forms interactions with M22 LC (Fig. 3A  and C) . Both, M22 and K1-18 interact with almost the whole concave surface including the C-terminal region of the TSHR LRD.
In the predicted binding arrangements, RSR-B2 interacts with a similar region on the TSHR LRD as K1-70 but is rotated by w1508 about an axis perpendicular to the concave surface of the TSHR LRD (Fig. 3D) . RSR-B2 is unlikely to bind to the C-terminal region of the TSHR LRD in the predicted interactions and this is similar to the arrangements in the K1-70-TSHR LRD crystal structure.
In addition, the surface of TSH presents an equivalent positive patch surrounded by a circular negative patch to those observed on the surface of the MAbs (M22, K1-18, K1-70 and RSR-B2) that interacts with complementary charged patches on the TSHR LRD (Fig. 3E) in the model of the TSH-TSHR LRD complex (Nú ñez Miguel et al. 2008) .
TSHR residue mutations that affect the activity of K1-18 and RSR-B2 are shown in Fig. 3C , D and Table 4 and are located within the area where the antibodies are predicted to bind. Furthermore, the TSHR residues that affect the biological activity of TSH (Table 4) A clear difference can be observed between thyroidstimulating and thyroid-blocking monoclonal antibodies in their interactions with the electrostatic potential patches located at the C-terminus of the TSHR LRD (Table 4) . Interactions of TSHR stimulators TSH, M22 and K1-18 involve regions at the C-terminus of the TSHR LRD (Fig. 4) , whereas interactions with TSHR-blocking antibodies do not (Table 4 and Fig. 4) . (Sanders et al. 2011) showing the residues that when mutated reduce the stimulating activity of human monoclonal autoantibody K1-18 (in red), the residues that when mutated do not affect the activity of K1-18 (in blue), and the residues for which the effect of mutation on the activity of K1-18 was not clear (in yellow). The N-terminal and C-terminal residues are marked. The mutated TSHR residues are labelled. Reproduced with permission from copyright holder RSR Ltd. Furthermore, the predicted model of TSHR LRD bound to a thyroid-blocking mouse MAb RSR-B2, for which a high-resolution crystal structure was also available , is described. The crystal structures of TSHR LRD in complex with M22 and K1- R109  N110  N110  N110  T111  R112  K129   e   K129  K129  F130  F130   e   F130  F134  N135  D151   e   D151  I152  I152  F153  F153   e   F153  I155  I155  I155  E157  E157  E157  E157  D160  D160  P162  T181  K183   e   K183  K183   e   Y185   e   Y185  D203  D203  Y206  N208  K209  K209   e   D232  Q235  K250  E251 E251 R255 (2006, 2010) . e Amino acids identified in the crystal structures, which when mutated affected the activity of the K1-70 or M22. f W258 was also found to be important for M22-stimulating activity in mutation studies (Table 3) ; however, there was no electron density for this residue in the M22-TSHR crystal structure (Sanders et al. 2007a) .
70 allowed us to identify unique electrostatic surface potential complementarities between the TSHR and the M22 and K1-70 antibody interacting surfaces (Sanders et al. 2007a (Sanders et al. , 2011 . In this study we predicted the positions of K1-18 and RSR-B2 on the TSHR LRD using charge-charge interaction mapping based on electrostatic surface potential complementarities. This strategy was validated by positioning M22 and K1-70 on the TSHR LRD using the same method and produced similar binding arrangements as those observed in the crystal structures of the respective complexes ( Fig. 3 ; Sanders et al. 2007a Sanders et al. , 2011 . In the predicted complex, K1-18 binds to the TSHR in a similar orientation to M22 but rotated about an axis perpendicular to the concave surface of the TSHR LRD by about 1908 (Fig. 3) . In the predicted binding arrangements, K1-18 interacts across the whole concave surface of the TSHR LRD including the C-terminal part similar to M22 and TSH binding (Sanders et al. 2007a , Nú ñez Miguel et al. 2008 . (Fig. 1) . However, in the case of K1-18, the negative charge is contributed mostly by residues from the HC and the positive charge from the LC, while this is the opposite way round for M22 (Sanders et al. 2007a , Nú ñez Miguel et al. 2009 ). Therefore, both of the thyroid-stimulating human antibodies M22 and K1-18 appear to mimic TSH interactions with the TSHR LRD (albeit using different antibody chains) and it may well be that this is a feature of thyroid-stimulating human autoantibodies in general.
Based on charge-charge interaction, mapping the thyroid-blocking mouse MAb RSR-B2 is predicted to bind to a large area on the concave surface of the LRD similar to the thyroid-blocking human MAb K1-70. However the position of RSR-B2 on the TSHR LRD is rotated by w1508 about an axis perpendicular to the concave surface of the TSHR LRD when compared with the position of K1-70 (Fig. 3) . In the predicted model RSR-B2 is not involved in interactions with the C-terminal region of the concave surface of the TSHR LRD, and this scenario is similar to the K1-70 binding arrangements in the crystal structure with TSHR-260 (Sanders et al. 2011) . Furthermore, analysis of the predicted interactions between RSR-B2 and the TSHR shows that RSR-B2 HC and LC do not mimic the TSH-a and -b chains in their interactions with the receptor, and the same situation was observed in the case of K1-70 (Sanders et al. 2011) .
The charge-charge interaction mapping method was validated by studying the effects of different TSHR mutations on the activities of both K1-18 and RSR-B2. All of the mutated TSHR residues shown to affect the stimulating activity of K1-18 or the blocking activity of RSR-B2 (Tables 3 and 4) were located within the interacting area of the predicted K1-18-TSHR and RSR-B2-TSHR complexes respectively (Fig. 3C and D) . K-18 is predicted to bind to the whole of the concave surface of the TSHR LRD. This included the C-terminal end of the LRD-containing residues identified as most important for the stimulating activity of K1-18 (E157, K183, Y185, D232, R255 or W258; Tables 3 and 4) in leucine-rich repeats (LRRs) 6-10. By contrast, the TSHR residues found to be important for RSR-B2-blocking activity (K58, R80, Y82, R109 and K129; Table 4 ) were from the N-terminal end of the LRD; LRRs 1-5. This is similar to the binding epitope for the blocking mouse MAb 1H7, which was reported to interact with TSHR residues T56, K58, R80, Y82, R109, F130, G132 and F134, i.e. the TSHR N-terminus (Costagliola et al. 2004) .
Although TSHR mutation R255A had no effect on the stimulating activity of K1-18, the change of charge mutation (R255D) resulted in a complete loss of K1-18 stimulating activity. In the predicted binding model, TSHR R255 would interact with a negative patch on K1-18 (Fig. 3C) . Substitution of R255 with a strongly negative aspartic acid (R255D mutation) would introduce repulsion and would reduce K1-18-binding affinity to the mutated TSHR.
The importance of interactions with R255 in the C-terminus of the TSHR LRD for stimulation of cyclic AMP production has been demonstrated previously for M22, mouse TSMAbs 1-7, a hamster MAb MS-1 and patient serum TRAb (Sanders et al. 2006) . The blocking activity of K1-70 was unaffected by TSHR R255D mutation while the blocking activity of RSR-B2 was increased (Sanders et al. 2006 (Sanders et al. , 2011 . Furthermore, TSHR stimulation by TSH was not affected by R255 mutations (Sanders et al. 2006) . However, the epitopes for another two thyroid-stimulating mouse MAbs, IRI-Sab2 and IRS-Sab3 (Costagliola et al. 2004) , on the TSHR were reported to involve residues T56, K58, I60, R80, Y82, S84, I85, H105, and I60, E61, Y82, I85, E107, R109, F130, G132, F134, at the N-terminus of the LRD. Although these binding residues overlap with our human and mouse stimulating MAb epitopes, TSHR R255 was not reported to be important for binding of IRI-Sab2 and IRA-Sab3 in FACs analysis and no cAMP response studies were carried out. However, IRI-Sab2 and IRI-Sab3 showed 66 and 61% binding, respectively, to the T21 Chimera (E251R/R255T mutation) relative to WT TSHR in the FACs analysis (Costagliola et al. 2004) . By contrast, binding of the blocking antibody 1H7 was unaffected or increased at 117% (Costagliola et al. 2004) . These results suggest that the stimulating MAbs IRI-Sab2 and IRI-Sab3 may also interact with R255 and the C-terminal region of the receptor. Analysis of the effect of TSHR R255D changes of charge mutation on the biological activity of IRI-Sab2 and IRISab3 would be helpful to confirm the importance of R255 for TSHR stimulation by antibodies in general. An exception to this may be the mouse MAb IRI-Sab1 with a weak thyroid-stimulating activity (Costagliola et al. 2004) that was shown to bind to the N-terminus of the TSHR on the convex surface of the LRD rather than the concave surface. In addition, IRI-Sab1 showed poor inhibition of TSH or TRAb binding to the TSHR and is therefore not a representative of patient serum autoantibodies (Costagliola et al. 2004) .
This study provides further evidence that the binding sites on the TSHR for stimulating and blocking mouse antibodies are extensive and overlapping. However, binding of the TSHR-blocking human MAb (K1-70) and mouse TSHR-blocking antibodies (RSR-B2 and 1H7) preferentially involves the N-terminal part of the concave surface of the LRD rather than the C-terminal part (Costagliola et al. 2004 , Sanders et al. 2011 .
The exact location of the binding sites for blocking autoantibodies and stimulating autoantibodies on the TSHR molecule has been controversial. Early studies with TSHR chimeras concluded that the major binding sites for thyroid-stimulating autoantibodies were located at the N-terminus of the TSHR amino acids 9-165 (Tahara et al. 1991 , Kosugi et al. 1993 , Kim et al. 1996 , Minich & Loos 2000 , Kung et al. 2001 , Minich et al. 2004 , while the epitopes of blockingtype autoantibodies were more towards the TSHR C-terminus (aa 261-370; Tahara et al. 1997 , Minich & Loos 2000 , Kung et al. 2001 . By contrast, experimental evidence from our laboratory (Sanders et al. , 2002 (Sanders et al. , 2006 (Sanders et al. , 2011 and other laboratories (Nagayama et al. 1991 , Rapoport et al. 1998 , Morgenthaler et al. 2003 suggests that the epitopes for both types of autoantibodies overlap extensively. Furthermore, analysis of the crystal structures of the TSHR complexed with a blocking MAb K1-70 and a stimulating MAb M22 clearly shows that the binding sites of the two antibodies overlap considerably on TSHR260 (aa 22-260; Sanders et al. 2007a Sanders et al. , 2011 . The current study predicts that the thyroid-stimulating human MAb K1-18 and the thyroid-blocking mouse MAb RSR-B2 also bind to TSHR260. This is in contrast to the previously reported TSHR epitope aa 261-370 important for blocking antibodies , Minich & Loos 2000 , Kung et al. 2001 , Loos et al. 2007 , which is missing entirely from the TSHR-260 construct. Furthermore, K1-70, K1-18 and M22 bind strongly to TSHR260 in a bridging ELISA (Rees ). In addition, over 50 patient serum TSHR autoantibodies interacted with TSHR260 (Rees ) including five sera with blocking activity and five sera with stimulating activity. However, a report (Schwarz-Lauer et al. 2002) in which the TSHR-blocking activity of one patient serum could not be absorbed by purified TSHR289 (aa 22-289), even though the blocking antibodies in a different serum and all the stimulating antibodies studied were absorbed, could indicate that occasional patient autoantibodies with blocking activity might bind outside the TSHR260 region.
It is possible that activation of the TSHR may involve changes in the relative positions of the TSHR LRD, the cleavage domain (CD) and/or the extracellular loops of the transmembrane domain (TMD) in the TSHR molecule (Szkudlinski et al. 2002 , Vlaeminck-Guillem et al. 2002 , Moyle et al. 2004 , Kleinau & Krause 2009 ). Interactions of antibodies with the C-terminal region of the TSHR LRD may trigger modification of the relative position of the three domains leading to receptor activation. Activation of the receptor by TSH is also likely to involve modification of the relative position of the three domains, although this may be achieved by a different mechanism not requiring interactions with the C-terminal region around TSHR R255. Experimental studies demonstrated that substitutions of aTSH residues T11, Q13, P16 and Q20 with lysine substantially increased TSHR-binding affinity and bioactivity (Szkudlinski et al. 1996) . These aTSH residues do not interact with the TSHR LRD in our model of the TSH-TSHR LRD complex and the equivalent aFSH residues do not interact with the FSHR LRD in the crystal structure of the FSH-FSHR LRD complex (Fan & Hendrickson 2005) . Consequently, it is possible that aTSH T11, Q13, P16 and Q20 interact with other domains of the receptor (Nú ñez , Mizutori et al. 2008 , Chen et al. 2010 . Three steps leading to TSHR activation were suggested by Kleinau & Krause (2009) including hormone binding, intramolecular signal transduction within the TSHR extracellular regions and finally transmission to the transmembrane region. In this scenario, specific multiple contacts between the hormone and the TSHR LRD would lead to selective hormone binding. The hormone would also contact the TSHR CD, and the TSHR LRD together with the CD would form a large hormone-binding pocket. This is in agreement with several studies that have shown that the TSHR CD is likely to have an important role as a signalling specificity domain (Mizutori et al. 2008 , Hamidi et al. 2011 ).
In the case of the LH receptor, a sequence T250-Q268 (equivalent to D276-G294 of the TSHR CD) was shown to specifically interact with hCG, preferentially hCGa. A close relationship between hCG and the LH receptor extracellular domain equivalent to TSHR CD and the extracellular loop 2 has been suggested (Zeng et al. 2001) . By contrast, however, it has been proposed that the extracellular loops 1 and 3 of the TMD of the FSHR have features of secondary binding sites and might interact with the ectodomain-bound aFSH (Dupakuntla & Mahale 2010) .
The available crystal structures of the TSHR in complex with M22 and K-70 provide valuable insight into how a stimulating and a blocking antibody bind to the TSHR and, together with extensive experimental studies, suggest that these arrangements reflect binding of TSHR antibodies in general (Sanders et al. 2006 (Sanders et al. , 2007a (Sanders et al. ,b, 2010 (Sanders et al. , 2011 . In the absence of further crystal structures of the TSHR in complex with other antibodies, we have used charge-charge interaction mapping methodology to predict binding of a new thyroid-stimulating human MAb K1-18 and a thyroidblocking mouse MAb RSR-B2 with the TSHR. The predicted binding arrangements were validated by the effects of the TSHR amino acid mutations on the biological activity of the MAbs, and the binding arrangements of the TSHR LRD with two stimulating (M22 and K1-18) and two blocking MAbs (K1-70 and RSR-B2) were compared. The limitation of this study is that it is based on a combination of evidence from high-resolution crystal structures (Sanders et al. 2007a (Sanders et al. , 2011 ), a comparative model (Nú ñez Miguel et al. 2008) , mutational analysis and more robust chargecharge interaction mapping. However, these studies showed that the binding sites for the TSHR antibodies with different biological activities overlap on the concave surface of the TSHR; however, stimulating antibodies show interactions with both the N-and C-terminus of the TSHR LRD while the blocking antibodies do not interact with the C-terminus. Whether this is the case for all TSHR-stimulating and -blocking antibodies (human and raised in animals) in general should be clarified with more TSHR MAbs as they may become available in the future. Understanding these interactions at the molecular level is likely to be useful in designing small molecules that would interfere with stimulating or blocking antibodies binding to the TSHR. Furthermore, this type of understanding may be helpful in future studies on how ligand-binding triggers TSHR activation.
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